biostudies-literatureBlum CASwiss National Science FoundationUniversität BaselNora van Meeuwen-Häfliger StiftungGottfried und Julia Bangerter-Rhyner-Stiftung21https://www.ebi.ac.uk/biostudies/studies/S-EPMC5307398biostudies-literatureUnknown18(1)<h4>Background</h4>In the emergency setting, non-traumatic headache is a benign symptom in 80% of cases, but serious underlying conditions need to be ruled out. Copeptin improves risk stratification in several acute diseases. Herein, we investigated the value of copeptin to discriminate between serious secondary headache and benign headache forms in the emergency setting.<h4>Methods</h4>Patients presenting with acute non-traumatic headache were prospectively enrolled into an observational cohort study. Copeptin was measured upon presentation to the emergency department. Primary endpoint was serious secondary headache defined by a neurologic cause requiring immediate treatment of the underlying disease. Secondary endpoint was the combination of mortality and hospitalization within 3 months.The journal of headache and painCopeptin for risk stratification in non-traumatic headache in the emergency setting: a prospective multicenter observational cohort study.PMC5307398PP0P3_123346PZ00P3_142422Biethahn SChrist-Crain MNigro NSchuetz PHaaf KMueller CBingisser RWinzeler BKatan MKahles TTepperberg JNedeltchev KBlum CAAmort MMuller BSandor PSTimper KHuber AfalseCopeptin for risk stratification in non-traumatic headache in the emergency setting: a prospective multicenter observational cohort study.<h4>Background</h4>In the emergency setting, non-traumatic headache is a benign symptom in 80% of cases, but serious underlying conditions need to be ruled out. Copeptin improves risk stratification in several acute diseases. Herein, we investigated the value of copeptin to discriminate between serious secondary headache and benign headache forms in the emergency setting.<h4>Methods</h4>Patients presenting with acute non-traumatic headache were prospectively enrolled into an observational cohort study. Copeptin was measured upon presentation to the emergency department. Primary endpoint was serious secondary headache defined by a neurologic cause requiring immediate treatment of the underlying disease. Secondary endpoint was the combination of mortality and hospitalization within 3 months.2017-01-01T00:00:00Z2017 Dec2026-06-14T03:16:34.819Z2019-03-27T02:36:25ZS-EPMC53073982819784310.1186/s10194-017-0733-2